

# Identification of triazolam, etizolam and their metabolites in biological samples by liquid chromatography tandem mass spectrometry

**ASMS 2012** WP28-611

Noriko Shoji<sup>1</sup>; Toshikazu Minohata<sup>2</sup>; Naohiro  
Kuriyama<sup>1</sup>; Chie Yokoyama<sup>1</sup>; Keiko Matsumoto<sup>2</sup>; Jun  
Watanabe<sup>2</sup>; Junko Iida<sup>2</sup>

<sup>1</sup>YMC Co., LTD., Komatsu, JAPAN

<sup>2</sup>Shimadzu Corporation, Kyoto, JAPAN

# Identification of triazolam, etizolam and their metabolites in biological samples by liquid chromatography tandem mass spectrometry

## Introduction

Benzodiazepines are one of the mostly widely prescribed groups of drugs because of their sedative, hypnotic, anxiolytic, antiepileptic and muscle relaxant properties. This class of compounds and their associated metabolites are also frequently present in clinical and forensic samples. For this reason, the analysis of benzodiazepines in biological fluids is of great importance to clinicians and forensic toxicologists. A key analytical challenge in the analysis of benzodiazepines is to identify etizolam, triazolam, and their

metabolites (alpha-hydroxyetizolam, 8-ethylhydroxyetizolam, alpha-hydroxytriazolam and 4-Hydroxytriazolam) as a mixture, because of their very similar chemical structure, molecular weight and fragmentation during mass spectrometry. In this study we report a new high resolution separating method for the simultaneous analysis of etizolam, triazolam and their metabolites.




Fig. 1 Structure of etizolam, triazolam and their metabolites



Fig. 2 LCMS-8030 triple quadrupole mass spectrometer

# Identification of triazolam, etizolam and their metabolites in biological samples by liquid chromatography tandem mass spectrometry

## Materials and Methods

Three samples were prepared: A) mixture of all standards (alpha-hydroxytriazolam, 4-hydroxytriazolam, triazolam and etizolam), B) metabolised matrix of triazolam and etizolam and C) blank metabolized matrix using human liver S9.

### *In vitro* metabolism of triazolam and etizolam in human liver S9:

Triazolam, etizolam, and NADPH regeneration system solution A (NADP<sup>+</sup>, Glucose-6-phosphate, MgCl<sub>2</sub> in H<sub>2</sub>O), NADPH regeneration system solution B (Glucose-6-phosphate dehydrogenase in sodium citrate buffer), human liver S9 were mixed in 100 mM phosphate buffer (pH 7.4). The mixture was incubated at 37 deg C

overnight (approx. 17 hrs). The control sample was prepared without triazolam and etizolam added. [Final concentration in incubation mixture; 100 mM triazolam and etizolam, 1.6 mM NADP, 3.3 mM Glucose-6-phosphate, 0.4 U/mL Glucose-6-phosphate dehydrogenase, 3.3 mM MgCl<sub>2</sub>, 2 mg/mL S9 protein

### Solid phase extraction (SPE) of incubation mixture:

The incubation mixture was extracted on YMC Dispo SPE C18 column (100 mg/mL) as follows and injected onto LC/MS/MS.

1. Condition with 2 mL MeOH
2. Equilibrate with 2 mL 0.1% CH<sub>3</sub>COOH
3. Load 250 mL sample
4. Elute with 1 mL MeOH
5. Dry extract and resolve in 500 mL H<sub>2</sub>O

Samples were analyzed with UHPLC and a triple quadruple mass spectrometer using following conditions

## Analytical Conditions

### HPLC: Nexera UHPLC system (Shimadzu Corporation, Japan)

Column: YMC-Triart C<sub>18</sub> column, 1.9 μm, 12 nm (150 × 2 mm)  
Mobile phase: (A) 10 mM formic acid  
(B) 10 mM formic acid / acetonitrile (1/1)  
Flow rate: 0.3 mL/min  
Time program: B conc. 40%(0 min)-65%(40 min)-40%(40.01-60 min)  
Injection volume: 1 μL  
Column temperature: 40°C

### Mass spectrometer: LCMS-8030 (Shimadzu Corporation, Japan)

Ionization: Electrospray ionization, Positive  
Scan type: multiple-reaction-monitoring mode (MRM)  
MRM triggered automatic MS/MS data acquisition

# Identification of triazolam, etizolam and their metabolites in biological samples by liquid chromatography tandem mass spectrometry

## Results

The simultaneous analysis of drugs of abuse in clinical and forensic laboratories requires highly specific methods. The developed method in this study contained not only optimized MRM transition parameters and chromatographic conditions, but also product ion scanning which is automatically triggered once an MRM exceeds a specified threshold. The method was applied to the analysis of benzodiazepines; including etizolam, triazolam, and their known metabolites. In this experiment three samples were prepared (as described above). Sample (A) was a matrix-free mixture of etizolam, triazolam, and their known metabolites, sample (B) was a

metabolized matrix of triazolam and etizolam and, sample (C) was a blank metabolism matrix of human liver S9. Firstly, sample (A) was analyzed with the method of 12 MRM transitions, which were quantitative and qualitative transitions for etizolam, triazolam, and their known metabolites and it resulted in excellent separation for all four compounds. Next, sample (C) (blank matrix) was analyzed and no peaks were observed; therefore highlighting the excellent selectivity of the method. Sample (B) (metabolized drug) was then analyzed and three new peaks were found (in addition to the four peaks in sample (A)).

compounds	Quantitative	CE	Qualitative	CE
Etizolam	343.05>314.10	-28	343.05>138.15	-37
Triazolam	343.05>308.20	-24	343.05>315.00	-27
8-Hydroxyetizolam (M -III)	359.05>305.05	-24	359.05>315.25	-20
alpha-Hydroxyetizolam (M-VI)	359.05>286.20	-28	359.05>287.20	-27
alpha-Hydroxytriazolam	359.05>176.20	-27	359.05>341.15	-18
4-Hydroxytriazolam	359.05>341.10	-22	359.05>111.20	-39




Fig. 3 12 MRM transitions for 6 drugs and metabolites (above) and MRM chromatograms for sample (A), (B), (C).

# Identification of triazolam, etizolam and their metabolites in biological samples by liquid chromatography tandem mass spectrometry

Two of the three unknown peaks were identified as 8-Ethylhydroxyetizolam and alpha-Hydroxyetizolam as they are known metabolites. However the third unknown peak, which was detected the same MRM transition as that of metabolites of these two compounds, was not identified. Next, sample (B) was re-acquired with MRM triggered

automatic MS/MS and product ion scans. These product ion scan spectra were searched against a hypnotics MS/MS library and the six previously identified peaks were assigned a high hit score. In the same manner as described here, this method is highly applicable to the screening of drugs of abuse in biological samples.

Type	Event#	+/-	Compound Name	m/z	Time (0.000 min - 50.000 min)
MRM	1	+	8-Hydroxyetizolam (M-III)	359.05>305.05	
- Product Ion Scan	2	+	8-Hydroxyetizolam (M-III)	100.00 > 100.00:3	
MRM	3	+	alpha-Hydroxytriazolam	359.05>176.20	
- Product Ion Scan	4	+	alpha-Hydroxytriazolam	100.00 > 100.00:369.	
MRM	5	+	alpha-Hydroxyetizolam (M-VI)	359.05>286.2	
- Product Ion Scan	6	+	alpha-Hydroxyetizolam (M-VI)	100.00 > 100.	
MRM	7	+	4-Hydroxytriazolam	359.05>341.10	
- Product Ion Scan	8	+	4-Hydroxytriazolam	100.00 > 100.00:369.00	
MRM	9	+	Triazolam	343.05>308.20	
- Product Ion Scan	10	+	Triazolam	100.00 > 100.00:353.00	
MRM	11	+	Etizolam	343.05>314.10	
- Product Ion Scan	12	+	Etizolam	100.00 > 100.00:353.00	

Loop Time	
Start - End Time(min)	0.000 - 50.000
Event	12
Loop Time(sec)	0.666

Loop time < 1 sec.




Fig. 4 MRM triggered MS/MS method and MS/MS spectra of Peak 1 to Peak 7

## Conclusions

- Metabolite analysis using LC/MS/MS with small particle size column achieved high resolution separation for the
- simultaneous analysis of etizolam, triazolam and their metabolites.
- The metabolites were detected and confirmed with MRM triggered automatic MS/MS data acquisition.



Shimadzu Corporation  
[www.shimadzu.com/an/](http://www.shimadzu.com/an/)

For Research Use Only. Not for use in diagnostic procedures.  
The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.